RecruitingNot applicableNCT06819449
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients
Studying Leprosy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- South Valley University
- Principal Investigator
- Eisa Mohammed Hegazy, Assist. ProfDermatology, Venereology and Andrology. Faculty of Medicine,South Valley University
- Intervention
- Dapsone(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 5-60 years · All sexes
- Timeline
- 2024 – 2025
Study locations (1)
- Qina University hospital, South Valley University Hospital, Qina, Egypt
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06819449 on ClinicalTrials.govOther trials for Leprosy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06761469Leprosy Active Searching Trial in BrazilHospital Alemão Oswaldo Cruz
- RECRUITINGNCT06683690TGF β 1 Expression Related Gene PolymorphismAswan University
- RECRUITINGPHASE3NCT05597280Bedaquiline Enhanced Post ExpOsure Prophylaxis for LeprosyInstitute of Tropical Medicine, Belgium
- RECRUITINGPHASE2NCT05243654Efficacy and Tolerability of Adjunct Metformin for Multibacillary LeprosyOxford University Clinical Research Unit Indonesia
- RECRUITINGNANCT06222372Novel Interventions and Diagnostic Tests for LeprosyAnnemieke Geluk